files/journal/2022-09-03_18-51-40-000000_599.png

Research Journal of Medical Sciences

ISSN: Online 1993-6095
ISSN: Print 1815-9346
About US
Editors
Issues
Pages
Indexed in
140
Views
20
Downloads

Study of Androgen Receptor as a Quadruple IHC Marker in Breast Carcinoma in a Tertiary Care Centre

Avadh Kishore, Sumit Kumar, Ajay Kumar Gupta, Naresh N. Rai and Murari Dhanetwal
Page: 305-310 | Received 10 Jan 2024, Published online: 14 Feb 2024

Download Citation
https://doi.org/10.36478/10.59218/makrjms.2024.5.305.310

Full Text Reference XML File PDF File

Abstract

Breast tumor is second most common tumor in the world. Breast tumor may be defined on the ground of absence or presence of Estrogen receptor (ER), Progesterone receptor (PR), and over expression of Human epidermal growth factor receptor 2 (HER2). Absence of these hormonal receptor (ER, PR, and HER2), define as TNBC (Triple negative breast carcinoma). TNBC can be classified in four subtypes, Basal 1, Basal 2, Mesenchymal and Luminal androgen receptor (LAR). LAR is most perceptive for AR antagonists because of it depends on AR signaling pathway. AR perform major role in breast carcinoma treatment, AR Antagonist predominantly used in Tamoxifen (SERM) resistant and TNBC. BR grade and HR status of 80 surgically resected specimen of carcinoma breast were determined by routine histopathological examination and IHC. Allred scoring system were employed to evaluate HR status. Chi square test was applied to find association between dependent and independent variables and p<0.05 considered as level of significance. In all cases of breast carcinoma, androgen receptor was positive for 89.7%, 82.4% and 52.6% of ER, PR and Her 2 positive cases. Significant association was found between AR status and ER/PR status (p<0.05). The present study show androgen receptor (AR) is currently emerging as a new biomarker and a potential new therapeutic target in the treatment of breast carcinoma, and the findings of this study could have prognostic and therapeutic implications for treatment protocols that include androgen receptor agonists or antagonists in appropriate clinical settings.

How to cite this article:

Avadh Kishore, Sumit Kumar, Ajay Kumar Gupta, Naresh N. Rai and Murari Dhanetwal. Study of Androgen Receptor as a Quadruple IHC Marker in Breast Carcinoma in a Tertiary Care Centre.
DOI: https://doi.org/10.36478/10.59218/makrjms.2024.5.305.310
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2024.5.305.310